Immune Design (IMDZ) Names Sergey Yurasov SVP of Clinical Development and Chief Medical Officer
Tweet Send to a Friend
Immune Design (Nasdaq: IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced the appointment of Sergey Yurasov, M.D., Ph.D ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
